GSK Adds Another Cancer Drug in a $750 Million Deal. Is its Oncology Bet Getting Bigger?

GSK plc (NYSE:GSK) is adding another cancer drug to a pipeline that has been getting considerably more attention under CEO Luke Miels. The company has agreed to acquire full global rights to a trispecific T-cell engager from China-based Chimagen Biosciences in a deal worth up to $750 million. GSK (NYSE:GSK) plans to develop the experimental drug for multiple myeloma, adding another potential treatment to its blood-cancer portfolio.

READ ALSO: Pfizer vs. Abbott: Which Dividend Healthcare Stock Offers the Better Risk-Reward? 

For investors, the deal is another piece of GSK’s broader push into oncology. But unlike some of the cancer assets the company has acquired recently, this program is still a long way from potentially reaching the market.

Bull Case

The Chimagen deal fits directly into an area where GSK is already building a presence. The experimental therapy is a trispecific T-cell engager designed to bind T cells while simultaneously targeting two tumor-associated antigens. GSK says that approach has the potential to produce deeper and more durable responses than existing T-cell engagers while improving tolerability. Those benefits remain potential rather than demonstrated clinical outcomes, however, because the program has not yet entered human trials.

GSK plans to develop and commercialize the asset for multiple myeloma, where it already markets Blenrep. The FDA approved Blenrep in a combination regimen in October 2025, allowing the blood-cancer drug to return to the U.S. market nearly three years after it had been withdrawn. GSK also sees a sizeable market opportunity in T-cell engagers. Citing external commercial forecasts, the company says the U.S. TCE market for multiple myeloma is expected to exceed $10 billion by 2032.

DON’T MISS: Can GSK’s Hepatitis B Breakthrough Become a £2 Billion Opportunity?

The deal also builds on an existing relationship with Chimagen. In 2024, GSK agreed to acquire CMG1A46, a dual CD19/CD20 T-cell engager, for $300 million upfront and up to $550 million in additional development and commercial milestones. That program is already in Phase I development. More broadly, the latest transaction follows GSK’s $10.6 billion acquisition of lung-cancer specialist Nuvalent earlier this year, its largest acquisition in more than a decade. Together, the deals show how aggressively GSK is adding external assets to its oncology pipeline.

Bear Case

The biggest limitation is straightforward: GSK is buying a drug that has not yet entered clinical trials. The company expects the trispecific T-cell engager to begin Phase I testing in 2027. That means its potential efficacy and tolerability still need to be evaluated in humans. GSK describes the asset as having the potential to offer differentiated efficacy and safety over existing T-cell engagers, and these are development goals based on the drug’s design, not clinical results.

Investors should also be careful with the $750 million headline figure, as GSK will pay an upfront fee for full global rights, but neither GSK nor Reuters disclosed the size of that upfront payment. The remainder consists of success-based development and commercial milestone payments to Chimagen, meaning the entire $750 million is not an immediate cost.

The transaction also arrives during a much broader oncology expansion. Reuters described the deal as the latest step in an oncology building spree under Miels ahead of looming patent losses on GSK’s top-selling HIV medicines. The $10.6 billion Nuvalent acquisition earlier this year represents a much larger commitment to that strategy.

Conclusion

For GSK investors, the Chimagen deal is less about what this single drug can contribute today and more about the direction of the company’s pipeline. GSK is adding another multiple myeloma program, strengthening an existing relationship with Chimagen and continuing an oncology expansion that has already included the $10.6 billion acquisition of Nuvalent. But this particular asset remains at the earliest end of that pipeline.

That makes 2027 the first meaningful milestone to watch. Until the trispecific T-cell engager enters Phase I testing, its proposed advantages remain just that: potential advantages. GSK is giving itself another shot in oncology, but investors will need clinical data before knowing how valuable this one could become.

READ NEXT: Can Eli Lilly Catch Novo Nordisk in the Oral GLP-1 Race? AND Abbott vs. Intuitive Surgical: Is Consistent Growth Better Than Premium Growth? 

This article is originally published at Insider Monkey.